Business and Strategy Overview

Growth Journey

Key Milestones in the Success Journey

Business and Strategy Overview

Growth and Development Journey

Key Milestones in the Success Journey

A specialist operating analysis equipment in an Avalon Pharma laboratory
  1. 1998
    Avalon Pharma was established in 1998, and in the same year, it launched its first manufacturing facility, “Avalon 1,” under the umbrella of the Middle East Chemical Products Factory, marking the beginning of its operational activities.
  2. 2000
    Avalon entered the retail market in the Kingdom of Saudi Arabia in 2000, marking the beginning of its direct presence in the local market.
  3. 2002
    “Medico” was established, and distribution operations commenced.
  4. 2004
    We began expanding into regional markets by starting the export of our products to the GCC countries.
  5. 2006
    Avalon Pharma obtained a license from the Ministry of Health to manufacture pharmaceuticals, enhancing its production capabilities.
  6. 2010
    Avalon expanded into international markets, covering Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Palestine, Sudan, Yemen, and the United Arab Emirates.
  7. 2015
    “Avalon 2,” the company’s first research and development facility, was inaugurated alongside the launch of the second manufacturing facility, “Avalon 3,” to expand production capacity and drive innovation.
  8. 2021
    “Avalon 4” was launched, a state-of-the-art central warehouse designed to support logistics operations and enhance efficiency in distribution management.
  9. 2022
    The production capacity expansion of “Avalon 2” was completed, with actual operations commencing in the second quarter of 2024. During the year, the company underwent a significant strategic transformation, transitioning from a Limited Liability Company (LTD) to a Joint Stock Company (JSC).
  10. 2023
    Avalon Pharma announced its plan to offer 30% of its capital for public subscription and to list its shares on the Saudi Stock Exchange (Tadawul).
  11. 2024
    Successful completion of the initial public offering, with 6,000,000 shares offered at 82 per share. Launch of 39 new products, an unprecedented achievement reflecting growth and innovation. Implementation of the “ACE” strategy, focusing on Accelerate, Catalyze, and Expand, to ensure sustainable growth and leadership.